Johnson & Johnson (NYSE:JNJ) Stock Rating Lowered by Zacks Investment Research

Johnson & Johnson (NYSE:JNJ) Stock Rating Lowered by Zacks Investment Research


According to Zacks, "J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J's domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition.



from Biotech News